Introduction
The WHO 2016 guidelines for classification of tumours of the central nervous system integrates molecular genomic information with histological analysis. The central nervous system tumour service offers a range of tests for the differential diagnosis of CNS tumours, provides prognostic information, and may aid in treatment decisions or clinical trial recruitment.
Referral information
We require a minimum 4x5µM thick unstained sections from a pathology specimen, either slide mounted or as scrolls (scrolls are required for KIAA1549-BRAF fusion testing), which must have been reviewed by a histopathologist and be accompanied by a completed test request form, clearly stating the proportion of neoplastic cells in the block. For optimum detection of somatic mutations >20% neoplastic cell content is required (>30% for TERT promoter mutation testing). Referrals will be accepted from oncologists and pathologists. If MGMT hypermethylation or KIAA1549-BRAF fusion testing is requested in addition to another test, we require an additional 4x5µM sections.
Price & reporting times
Test | Technique | Price (£ ex VAT) | TRT |
---|---|---|---|
hTERT promoter mutations | Sanger sequencing | POA | 14cd |
MGMT promoter hypermethylation | Pyrosequencing | POA | 14cd |
1p19q co-deletion | FISH | POA | 14cd |
BRAF codon 600 mutations | Pyrosequencing/COBAS | POA | 14cd |
KIAA1549:BRAF fusion | Droplet Digital PCR | POA | 14cd |
C11orf95-RELA fusion | Droplet Digital PCR | POA | 14cd |
EGFRvIII Transcript | Droplet Digital PCR | POA | 14cd |
Meningioma/schwannoma panel | Next generation sequencing panel | POA | 14cd |
NGS Somatic cancer/ Glioma sub-panel | Next generation sequencing panel | POA | 14cd |
Test validation & quality assurance - information for users
Referral guidelines
Please see our referral guidelines for more information.